CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the Company will host a conference call on Monday, March 6, 2017 at 4:30 PM ET to discuss the financial results for the year ended December 31, 2016, and recent corporate highlights.
Conference Call and Webcast
Date: | March 6, 2017 | ||
Time | 4:30 PM ET | ||
Telephone Access: |
Domestic Callers: dial (877) 458-0977 International Callers: dial (484) 653-6724 Please reference the Akebia conference call Passcode: 77605143 |
||
Online Access: |
Go to the Investor Relations section of the Akebia website and follow instructions for accessing the live webcast. Please connect to the website at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. An archived presentation will be available for 90 days. |
||
Telephone Replay: |
A telephone replay will be available for 5 days following the call. Replay for domestic Callers: dial (855) 859-2056 Replay for international Callers: dial (404) 537-3406 Passcode: 77605143 |
||
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia's lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia's global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at www.akebia.com.